|
Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2. |
|
|
Honoraria - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron |
Consulting or Advisory Role - Aduro Biotech; Akeso Biopharma; Amgen; BeiGene; BioAtla; Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Idera; Immunocore; Incyte; Janssen; Merck; NextCure; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Zelluna |
Speakers' Bureau - Bristol-Myers Squibb; Novartis; Pfizer; Sanofi/Regeneron |
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst) |
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Blueprint Medicines; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; G1 Therapeutics; Genentech; Guardant Health; Inivata; Janssen Oncology; Jazz Pharmaceuticals; Lilly; MSD Oncology; Pfizer; PharmaMar; Regeneron; Takeda |
Research Funding - Alkermes (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Debiopharm Group (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Lilly (Inst); Lycera (Inst); Merck (Inst); Merus (Inst); Molecular Partners (Inst); Pfizer (Inst); Rain Therapeutics (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; MSD Oncology; Roche/Genentech |
|
|
Honoraria - Amgen; AstraZeneca; Blueprint Medicines; BMS; DSI; Genentech; Incyte; Janssen; Rigel |
Consulting or Advisory Role - Amgen; AstraZeneca; BMS; DSI; Genentech; Incyte; Janssen; Rigel |
Speakers' Bureau - Amgen; AstraZeneca; DSI; Genentech; Incyte; Janssen; Rigel |
Research Funding - Amgen (Inst); AstraZeneca (Inst); DSI (Inst); Genentech (Inst); Incyte (Inst); Janssen (Inst); Rigel (Inst) |
Travel, Accommodations, Expenses - Amgen; AstraZeneca; DSI; Genentech; Incyte; Janssen; Rigel |
|
|
No Relationships to Disclose |
|
Trisha Michel Wise-Draper |
Stock and Other Ownership Interests - High Enroll |
Honoraria - Physicans' Education Resource |
Consulting or Advisory Role - Exicure; Rakuten Medical; Shattuck Labs |
Research Funding - AstraZeneca/MedImmune; Bristol-Myers Squibb; Caris Life Sciences; GlaxoSmithKline; GlaxoSmithKline; Merck |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; bexion; Bristol-Myers Squibb; Caris Life Sciences; Lilly; Merck; Tesaro |
|
|
Consulting or Advisory Role - Rafael Pharmaceuticals |
Speakers' Bureau - Bristol-Myers Squibb; Merck |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Rafael Pharmaceuticals |
|
|
Employment - BioCytics; Carolina BioOncology Institute |
Leadership - BioCytics; Carolina BioOncology Institute |
Stock and Other Ownership Interests - BioCytics; Bluebird Bio; Carolina BioOncology Institute; Juno Therapeutics; Kite, a Gilead company; Lion Biotechnologies; ZIOPHARM Oncology |
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Curis; Genentech/Roche; TERUMO; TopAlliance BioSciences Inc |
Speakers' Bureau - Bristol-Myers Squibb; Dendreon; Genentech/Roche; Merck |
Research Funding - Abbvie; Alkermes; Apros Therapeutics; Arcus Biosciences; AstraZeneca/MedImmune; Atreca (Inst); BioBank Online (Inst); Bristol-Myers Squibb; Calico; CEM Corporation (Inst); Corvus Pharmaceuticals; Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); FLX Bio; Genentech/Roche; Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; Merck (Inst); MT Group (Inst); Precision for Medicine (Inst); Replimune (Inst); Seagen; Sequenom (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience |
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy |
Other Relationship - Ongoing discussions with potential future biopharma and biotech for Human Applications Lab sponsored projects |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Pfizer; Sanofi |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Pfizer |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi |
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Pfizer |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Pfizer; Sanofi |
Research Funding - Alkermes (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Checkmate Pharmaceuticals (Inst); Gan & Lee (Inst); GlaxoSmithKline (Inst); Glyconex (Inst); Immunocore (Inst); Intensity Therapeutics (Inst); Iovance Biotherapeutics (Inst); Kadmon (Inst); Kartos Therapeutics (Inst); Navire (Inst); Nektar (Inst); OncoSec (Inst); Regeneron (Inst); Seagen (Inst); Sound Biologics (Inst); Spring Bank (Inst); Sumitomo Group (Inst); Takeda (Inst); Targovax (Inst) |
(OPTIONAL) Uncompensated Relationships - Takeda |
|
|
Employment - Precision Genetics |
Leadership - Precision Genetics |
Stock and Other Ownership Interests - Precision Genetics |
Research Funding - Altor BioScience |
|
|
Consulting or Advisory Role - Caris Life Sciences; ImaginAb |
Speakers' Bureau - Caris Life Sciences |
Research Funding - Alkermes; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; H3 Biomedicine; Halozyme; Hutchison China Meditech; ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Taiho Pharmaceutical; Telix Pharmaceuticals; Xencor |
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget |
|
Sarina Anne Anne Piha-Paul |
Consulting or Advisory Role - Merck |
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); NIH/NCI (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Taiho Oncology (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst) |
|
|
|
Stock and Other Ownership Interests - Alkermes |
|
|
|
Stock and Other Ownership Interests - Alkermes |
|
|
|
Stock and Other Ownership Interests - Alkermes |
|
|
|
Stock and Other Ownership Interests - Alkermes |
|
|
|
Stock and Other Ownership Interests - Alkermes; Bristol-Myers Squibb |
|
|
|
Stock and Other Ownership Interests - Alkermes |
|
|
Stock and Other Ownership Interests - Bristol-Myers Squibb; GE Healthcare |
Consulting or Advisory Role - Alkermes; Bristol-Myers Squibb; EMD Serono; ImmuNext; Omniseq |
Research Funding - Alkermes (Inst); Bristol-Myers Squibb (Inst); EMD Serono; Merck (Inst); Merrimack (Inst) |
Travel, Accommodations, Expenses - Alkermes; ImmuNext |
Other Relationship - Bristol-Myers Squibb |